IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
NOVARTIS-YTB323A12101
Phase I
OPEN TO ACCRUAL
Phase 1, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL